SCHEMBL12148917

SCHEMBL12148917

CC(=O)O[C@H]1[C@@H](CO)OC2OC(C)(C)O[C@@H]21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 8/20 0.40
CA1 P00915 5/20 0.40
ALDH1A1 P00352 2/20 0.40
CA9 Q16790 2/20 0.40
HPGD P15428 1/20 0.39
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
THPO P40225 1/20 0.36
GLB1 P16278 1/20 0.36
CA12 O43570 3/20 0.35
CA4 P22748 3/20 0.35
CA5A P35218 3/20 0.35
CA7 P43166 3/20 0.35
CA5B Q9Y2D0 3/20 0.35
PRKCA P17252 2/20 0.35
PRKD3 O94806 1/20 0.35
PRKCG P05129 1/20 0.35
PRKCB P05771 1/20 0.35
PRKCH P24723 1/20 0.35
PRKCE Q02156 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17976917 1.00 CA2 (0.40) CA2CA1ALDH1A1CA9HPGD
SCHEMBL12150836 1.00 CA2 (0.40) CA2CA1ALDH1A1CA9HPGD
SCHEMBL28471974 0.90 HPGD (0.42) CA2CA1ALDH1A1CA9HPGD
SCHEMBL13845627 0.84 LMNA (0.39) CA2CA1ALDH1A1CA9HPGD
SCHEMBL13845597 0.82 ALDH1A1 (0.37) CA2CA1ALDH1A1CA9HPGD
SCHEMBL15691484 0.81 CA2 (0.41) CA2CA1ALDH1A1CA9HPGD
SCHEMBL12408768 0.81 CA2 (0.41) CA2CA1ALDH1A1CA9HPGD
SCHEMBL19132623 0.81 CA2 (0.41) CA2CA1ALDH1A1CA9HPGD
SCHEMBL29329357 0.81 CA2 (0.41) CA2CA1ALDH1A1CA9HPGD
SCHEMBL8960307 0.81 CA2 (0.41) CA2CA1ALDH1A1CA9HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9227992-B2 Method of preparing deoxyribofuranose compounds ANADYS PHARMACEUTICALS, INC. (US) 2016-01-05 US disclosed
US-20140350231-A1 METHOD OF PREPARING DEOXYRIBOFURANOSE COMPOUNDS ANADYS PHARMACEUTICALS INC (US) 2014-11-27 US disclosed
US-8829168-B2 Method of preparing deoxyribofuranose compounds ANADYS PHARMACEUTICALS, INC. (US) 2014-09-09 US disclosed
US-20110288282-A1 METHOD OF PREPARING DEOXYRIBOFURANOSE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2011-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140350231-A1 METHOD OF PREPARING DEOXYRIBOFURANOSE COMPOUNDS DUT, DPYD, DERA CA2 4666/4885CA1 4241/4885ALDH1A1 240/4885
US-20110288282-A1 METHOD OF PREPARING DEOXYRIBOFURANOSE COMPOUNDS DUT, DPYD, DERA CA2 4666/4885CA1 4241/4885ALDH1A1 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.